Cargando…

Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels

This study was to determine the association between several single nucleotide polymorphisms (SNPs) in the dedicator of cytokinesis 7 (DOCK7), proprotein convertase subtilisin/kexin type 9 (PCSK9) and polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2) and serum lipid levels. Genotyping of 9 SNP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Tao, Yin, Rui-Xing, Huang, Feng, Yao, Li-Mei, Lin, Wei-Xiong, Pan, Shang-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705473/ https://www.ncbi.nlm.nih.gov/pubmed/26744084 http://dx.doi.org/10.1038/srep19079

Ejemplares similares

Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia
por: Guo, Tao, et al.
Publicado: (2015)

Association of the GALNT2 gene polymorphisms and several environmental factors with serum lipid levels in the Mulao and Han populations
por: Li, Qing, et al.
Publicado: (2011)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

Integrative mutation, haplotype and G × G interaction evidence connects ABGL4, LRP8 and PCSK9 genes to cardiometabolic risk
por: Guo, Tao, et al.
Publicado: (2016)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
por: Chuan, Junlan, et al.
Publicado: (2019)

Association between the MVK and MMAB polymorphisms and serum lipid levels
por: Miao, Liu, et al.
Publicado: (2017)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Association between the PINX1 and NAT2 polymorphisms and serum lipid levels
por: Zhang, Qing-Hui, et al.
Publicado: (2017)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
por: Qiu, Chengfeng, et al.
Publicado: (2017)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population
por: Wu, Huangfu, et al.
Publicado: (2019)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Association of the SPTLC3 rs364585 polymorphism and serum lipid profiles in two Chinese ethnic groups
por: Zhang, Qing-Hui, et al.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 Are Associated with Serum Lipid Profile in Chinese Han Population
por: Li, Zheng, et al.
Publicado: (2019)

DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke
por: Li, Wei-Jun, et al.
Publicado: (2018)

Role of GALNT2 on Insulin Sensitivity, Lipid Metabolism and Fat Homeostasis
por: Antonucci, Alessandra, et al.
Publicado: (2022)

Association of genetic polymorphisms of GALNT3 and VDR with osteoporosis in postmenopausal women
por: Wang, Guorong, et al.
Publicado: (2016)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

The SRGAP2 SNPs, their haplotypes and G × E interactions on serum lipid traits
por: Miao, Liu, et al.
Publicado: (2017)

Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood
por: Peticca, Patricia, et al.
Publicado: (2013)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

High expression of GALNT7 promotes invasion and proliferation of glioma cells
por: Hua, Shi, et al.
Publicado: (2018)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations
por: Aung, Lynn Htet Htet, et al.
Publicado: (2011)

ATP-Binding Cassette Transporter G5 and G8 Polymorphisms and Several Environmental Factors with Serum Lipid Levels
por: Li, Qing, et al.
Publicado: (2012)

Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
por: Alannan, Malak, et al.
Publicado: (2022)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
por: Naber, Annemieke, et al.
Publicado: (2023)

Acute TSH stimulation in vivo does not alter serum PCSK9 levels
por: Gagnon, AnneMarie, et al.
Publicado: (2014)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o6d4k6l9rib94qt6mm0mo7nl5j